Cubist to promote AstraZeneca's Merrem IV in the US
This article was originally published in Scrip
Cubist Pharmaceuticals has signed an exclusive agreement with AstraZeneca to promote the broad-spectrum antibiotic Merrem IV (meropenem for injection) in the US. Cubist will promote the product using its existing US acute care sales and medical affairs organisations, while AstraZeneca will continue to provide marketing and commercial support. The agreement establishes a baseline of $20 million annual revenue to Cubist, which will be adjusted on actual product sales. Other terms of the deal were not disclosed.